🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

17 recruiting trials

for Recurrent Meningioma

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma NCT07150806Phase 1, Phase 21 site📍 Columbus Joshua Palmer · Tests: Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography, Echocardiography Test, Gallium Ga 68-DOTA… 177Lu-DOTATATE for Recurrent Meningioma NCT06326190Phase 219 sites📍 Innsbruck📍 Vienna📍 Lyon European Organisation for Research and Treatment of Cancer … · Tests: Local standard of Care, 177Lu-DOTATATE Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults NCT04501705NA1 site📍 Beijing Beijing Sanbo Brain Hospital · Tests: Apatinib Mesylate Regorafenib for Recurrent Meningioma (MIRAGE Trial) NCT06275919Phase 220 sites📍 Meldola📍 Messina📍 Bagno a Ripoli Istituto Oncologico Veneto IRCCS · Tests: Regorafenib 40 MG Oral Tablet, Local Standard of Care Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) NCT04427384n/a54 sites📍 Phoenix📍 Little Rock📍 Castro Valley GT Medical Technologies, Inc. · Tests: GammaTile Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study NCT07398170NA1 site📍 Montpellier University Hospital, Montpellier · Tests: Blood sampling, Lumbar puncture Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide NCT04997317Phase 1, Phase 21 site📍 Basel University Hospital, Basel, Switzerland · Tests: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over),… A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma NCT07428616Phase 220 sites📍 Birmingham📍 Phoenix📍 San Francisco Exelixis · Tests: Zanzalintinib Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma NCT06557512NA1 site📍 San Francisco University of California, San Francisco · Tests: Hypofractionated Stereotactic Radiosurgery (SRS), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Cabozantinib for Patients With Recurrent or Progressive Meningioma NCT05425004Phase 23 sites📍 Miami📍 New York📍 Nashville Baptist Health South Florida · Tests: Cabozantinib NEO100 and High-Grade Meningioma NCT05023018Phase 25 sites📍 Los Angeles📍 San Francisco📍 Santa Monica Neonc Technologies, Inc. · Tests: NEO100 A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma NCT07533942Phase 25 sites📍 San Francisco📍 New Orleans📍 Boston Jazz Pharmaceuticals · Tests: JZP3507 Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy NCT04082520Phase 21 site📍 Rochester Mayo Clinic · Tests: Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnai… Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082Phase 11 site📍 Bethesda Jazz Pharmaceuticals · Tests: ONC206 Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208Phase 1, Phase 24 sites📍 Aurora📍 Cincinnati📍 Columbus Nationwide Children's Hospital · Tests: LUTATHERA® (Lutetium Lu 177 dotatate) Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas NCT02523014Phase 2784 sites📍 Birmingham📍 Anchorage📍 Anchorage Alliance for Clinical Trials in Oncology · Tests: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy